Quintiles,an integrated biopharmaceutical company, has been named a preferred provider to a consortium of 14 global health Product Development Partnerships (PDPs), funded in part by the Bill and Melina Gates Foundation . PDPs are not-for-profit entities formed for the purpose of advancing global health and the health of the world’s poorest by the discovery, development and delivery of new effective and affordable medicines for the most neglected diseases in the world.

The 14 PDPs anticipate funding 128 phase I-IV clinical trials over the next two years 2011-2013. The Bill and Melinda Gates Foundation has committed $10 billion over the next 10 years to help research, develop and deliver vaccines and treatments for the world’s poorest countries, with a portion of that commitment directed to the PDPs. The PDPs also receive funding from government agencies, private entities and other sources.

Quintiles will partner with the consortium members by providing one-step access to Quintiles’ global clinical development infrastructure and standards, particularly in the area of infectious diseases such as HIV, malaria and tuberculosis.

“Quintiles is extremely pleased to have been chosen by the consortium members,” said Dr. Kelly McKee, M.D., Quintiles Vice President and Managing Director, Public Health and Government Services. “The work they’re doing has the potential to reshape global health within a generation. The public health issues on which they are focused has the potential to save millions of lives. We are very excited to be named a preferred provider to the consortium and look forward to helping advance this critical mission.”

Source: Business Wire